Friday, October 21, 2016 9:47:25 PM
1. Lack of dilution/selling: Our number one worry after an R/S is the price going down, yet I have not noticed any major dilution or selling by BLDV and now they have some revenues to be self sufficient. Notice the lack of significant increase in the o/s in the past year.
2. Stability and rational management: I find BLDV has become a stable company with rational management that does not put out fluff PRs just to pump the pps to go high with baseless support. To the contrary, BLDV does not release PRs often and only when they have achieved something. This stability and rational management will help support a stable pps post-R/S.
3. Intrinsic value: BLDV seems to be more focused on building long-term value into the corporation that will inherently increase the intrinsic value of the pps rather than managing the pps based on what we have seen so far. This approach will provide sustained long-term growth and support to a post-R/S pps which is what we need.
4. Strategic a/s level: The filing also decreases the a/s to 880M which leaves only 404M if the post R/S o/s is assumed to be 476M. That does not leave a lot of room to dilute post R/S yet strategically gives BLDV enough flexibility to pursue acquisitions or mergers if they decide to in the future. Notice the strategic approach to the a/s level while being at a level that reassures us as shareholders.
See section 3.1 for new proposed a/s in the filing: http://www.sos.state.co.us/biz/ViewImage.do?fileId=20161437584&masterFileId=20161257384
5. Attractive share structure: The size of the R/S is also strategic to achieve the good insight that doog very well pointed out in post 46740 and make the share structure more attractive for future investors to be interested to buy BLDV and carry the pps higher with a 476M o/s and a 880M a/s. This is further supported by timmage's great explanation in post 46753.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125966897
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=125972070
6. Timing: Notice how BLDV seems to be working on quite a few initiatives but has not released any official PRs yet. It would be smart timing if the R/S is completed before any significant PRs are released which would help ensure the pps stays at a higher level post R/S. Time will tell if this will happen.
Based on the above factors, I think the probability is low that the BLDV pps will sell off and decrease after the R/S if they go ahead with it; this is all imo.
If anyone has any other thoughts, please share them.
Buy cautiously and sell reluctantly. All of my posts are In My Opinion only based on the DD I have completed. Please do your own DD and make your own decisions.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM